

16 December 2021

Our Ref: RFI 41411

Dear

**Freedom of Information Act 2000
Information in Relation to the usage of systemic anti-cancer therapies**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 21 October 2021.

Please accept my apologies for the delay in responding to your request, due to the impact of Winter Pressures that the Trust are currently facing. Thank you for your understanding and forbearance of this matter.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Assistant

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?

A1. Please see Table One below which details the number of patients that have been treated for any stage of breast cancer in the past 3 months with the systemic anti-cancer therapies listed.

Table One

<u>Treatment</u>	<u>No of patients</u>
<i>Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent</i>	Please refer to A2
<i>Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)</i>	Nil
<i>Abemaciclib + Fulvestrant</i>	Nil
<i>Anthracycline (e.g. doxorubicin or epirubicin) as a single agent</i>	Nil
<i>Atezolizumab +Nab-paclitaxel/Paclitaxel</i>	Nil
<i>Capecitabine as a single agent</i>	<5*
<i>Carboplatin or Cisplatin as a single agent</i>	<5*
<i>Eribulin as a single agent or in combination</i>	Nil
<i>Everolimus + Exemestane</i>	Nil
<i>Fluorouracil</i>	Nil
<i>Fulvestrant as a single agent</i>	Nil
<i>Goserelin</i>	Nil
<i>Lapatinib</i>	Nil
<i>Neratinib</i>	Nil
<i>Olaparib</i>	Nil
<i>Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)</i>	Nil
<i>Palbociclib + Fulvestrant</i>	<5*

A1. Cont'd

Table One cont'd

<u>Treatment</u>	<u>No of Patients</u>
<i>Pertuzumab + Trastuzumab + Docetaxel</i>	Nil
<i>Platinum (e.g. carboplatin or cisplatin) as a single agent</i>	<5*
<i>Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)</i>	Nil
<i>Ribociclib + Fulvestrant</i>	Nil
<i>Talazoparib</i>	Nil
<i>Tamoxifen</i>	Nil
<i>Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent</i>	<5*
<i>Transtuzumab as a single agent</i>	<5*
<i>Trastuzumab emtansine</i>	Nil
<i>Transtuzumab deruxtecan</i>	Nil
<i>Any other active systemic anti-cancer therapy</i>	N/A

You will note that some of the numbers within the Attachment have been masked. The numbers have been masked because there are a small number of individuals within a small geographical area and therefore the individual could be identified. Potential Identification of the individual may therefore lead to the disclosure of their personal information.

This information relates to personal information, it is exempt from release under Section 40 (2) and 40 (3) (a) of the Freedom of Information Act, 2000. Section 40 (personal information) states:-

(2)Any information to which a request for information relates is also exempt information if—

(a) it constitutes personal data which not fall within subsection (1), and
(b) the first, second or third condition below is satisfied.

(3)The first condition is that the disclosure of the information to a member of the public otherwise than under this Act—

(a) would contravene any of the data protection principles.

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

A2. There is currently no method, other than a manual audit to identify early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent patients within SET.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.